Javascript must be enabled to continue!
A study of tolerance to apomorphine
View through CrossRef
The present study was designed to investigate tolerance to several pharmacological effects of apomorphine.Changes in blood pressure, heart rate, plasma noradrenaline levels, rectal temperature, respiratory rate and retching plus vomiting were compared after administration of apomorphine (200 μg kg−1, i.v. as a bolus) or saline at different time intervals (30, 120 and 720 min) in four groups of chloralose‐anaesthetized dogs.The first administration of apomorphine induced a significant decrease in blood pressure and rectal temperature, a marked rise in heart rate with no change in noradrenaline plasma levels or respiratory rate. Emesis occurred in 71% of the animals.A second administration of apomorphine 30 min later failed to modify blood pressure or heart rate. In contrast, the magnitude of apomorphine‐induced changes in blood pressure and heart rate was similar to that observed after the first administration when apomorphine was given 120 or 720 min later.The apomorphine‐induced decrease in rectal temperature evoked by a second dose of apomorphine was less marked when given 30 and 120 min after the first dose and unchanged when given 720 min later.The number of animals exhibiting retching and vomiting was lower when apomorphine was reinjected after 30 min than when the time between two successive injections of apomorphine was 120 or 720 min.These results show that tolerance to apomorphine involves its cardiovascular, hypothermic and emetic effects. The time course of tolerance to repeated injections of apomorphine is longer for its hypothermic than for its hypotensive or emetic effects. This suggests a tissue‐specific regulation of D2dopamine receptors to repeated injections of apomorphine.
Title: A study of tolerance to apomorphine
Description:
The present study was designed to investigate tolerance to several pharmacological effects of apomorphine.
Changes in blood pressure, heart rate, plasma noradrenaline levels, rectal temperature, respiratory rate and retching plus vomiting were compared after administration of apomorphine (200 μg kg−1, i.
v.
as a bolus) or saline at different time intervals (30, 120 and 720 min) in four groups of chloralose‐anaesthetized dogs.
The first administration of apomorphine induced a significant decrease in blood pressure and rectal temperature, a marked rise in heart rate with no change in noradrenaline plasma levels or respiratory rate.
Emesis occurred in 71% of the animals.
A second administration of apomorphine 30 min later failed to modify blood pressure or heart rate.
In contrast, the magnitude of apomorphine‐induced changes in blood pressure and heart rate was similar to that observed after the first administration when apomorphine was given 120 or 720 min later.
The apomorphine‐induced decrease in rectal temperature evoked by a second dose of apomorphine was less marked when given 30 and 120 min after the first dose and unchanged when given 720 min later.
The number of animals exhibiting retching and vomiting was lower when apomorphine was reinjected after 30 min than when the time between two successive injections of apomorphine was 120 or 720 min.
These results show that tolerance to apomorphine involves its cardiovascular, hypothermic and emetic effects.
The time course of tolerance to repeated injections of apomorphine is longer for its hypothermic than for its hypotensive or emetic effects.
This suggests a tissue‐specific regulation of D2dopamine receptors to repeated injections of apomorphine.
Related Results
Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
AbstractWe investigated whether administration of the catechol‐O‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomo...
Apomorphine hydrochloride: a clinical review with retrospective analysis of use in 1126 dogs treated in emergency practice
Apomorphine hydrochloride: a clinical review with retrospective analysis of use in 1126 dogs treated in emergency practice
Apomorphine is a non-selective dopamine agonist commonly used in veterinary medicine for the emergency management of toxicoses in dogs, through the induction of emesis. This review...
Efficacy and safety of apomorphine in the treatment of Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials
Efficacy and safety of apomorphine in the treatment of Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials
Background:
Motor fluctuations and OFF episodes are common complications of long-term levodopa therapy in Parkinson’s disease (PD) and significantly impair qual...
The effects and D2 receptor-mediated mechanisms of dopaminergic system modulation in in-vivo and in-vitro experimental models of migraine
The effects and D2 receptor-mediated mechanisms of dopaminergic system modulation in in-vivo and in-vitro experimental models of migraine
The dopaminergic system is implicated in the pathophysiology of
migraine. However, the underlying mechanisms remain unclear. We explored
the effects and mechanisms of dopaminergic ...
Les faces cachées de l’apomorphine : leçons passées, contributions expérimentales actuelles et défis futurs
Les faces cachées de l’apomorphine : leçons passées, contributions expérimentales actuelles et défis futurs
Doyenne de la thérapeutique antiparkinsonienne, puissant outil pharmacologique au profil singulier, l’apomorphine est aujourd’hui indiquée comme thérapeutique de deuxième intention...
Development and validation of a rapid HPLC-UV method for simultaneous quantification of apomorphine and related impurities in drug products
Development and validation of a rapid HPLC-UV method for simultaneous quantification of apomorphine and related impurities in drug products
Abstract
Apomorphine, a potent dopamine agonist, plays a significant role in the management of advanced Parkinson's disease, and requires careful monitoring of th...
Pharmacokinetics of apomorphine in parkinsonian patients
Pharmacokinetics of apomorphine in parkinsonian patients
Summary— Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa‐induced on‐off phenomenon. Motor improvement has been obtained...
EFFECT OF APOMORPHINE ON ADRENAL MEDULLARY CATECHOLAMINE LEVELS
EFFECT OF APOMORPHINE ON ADRENAL MEDULLARY CATECHOLAMINE LEVELS
Summary—The effects of the dopamine receptor agonist, apomorphine, on the total catecholamine content of the adrenal medulla were studied in normotensive rats. Apomorphine (3, 15, ...

